Aleksandar Sekulic

Aleksandar Sekulic M.D.

Associate Professor
Integrated Cancer Genomics Division

Aleksandar Sekulic M.D.

Dr. Aleksandar Sekulic is a physician-scientist with a joint appointment as Associate Professor at TGen and the Mayo Clinic Arizona. He is a board certified in dermatology. Dr. Sekulic joined TGen to focus on translational research related to cutaneous oncology, melanoma, genetics of skin disease, and cancer biology.

Dr. Sekulic received his medical degree from the University of Zagreb in Zagreb, Croatia and completed dermatology residency and fellowship training at Mayo Graduate School of Medicine in Rochester, Minnesota. In addition, he completed his graduate work in the Department of Immunology at the Mayo Graduate School in Rochester, MN.

  • Sekulic A, Kim SY, Hostetter G, Savage S, Einspahr JG, Prasad A, Sagerman P, Curiel-Lewandrowski C, Krouse R, Bowden T, Warneke J, Alberts DS, Pittelkow MR, DiCaudo D, Nickoloff BJ, Trent JM, Bittner M, Loss of Inositol Polyphosphate 5-Phosphatase Is an Early Event in Development of Cutaneous Squamous Cell Carcinoma. Cancer Prev Res 3(10); 1277-83 2010
  • Sekulic A, Colgan MB, Davis MD, Dicaudo DJ, Pittelkow MR., Activating BRAF Mutations in Eruptive Melanocytic Nevi. Br J Dermatol Epub ahead of print 2010
  • Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, Mattar BI, Nikcevich DA, Novotny P, Sekulic A, Loprinzi CL., Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4) Oncologist 15(9):1016-22. 2010
  • Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT. , A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin In mitogen-stimulated and transformed cells Cancer Res 60(13):3504-13 2009
  • Markovic SN, Erickson LA, Flotte TJ, Kottschade LA, McWilliams RR, Jakub JW, Farley DR, Tran NV, Schild SE, Olivier KR, Vuk-Pavlovic S, Sekulic A, Weenig RH, Pulido JS, Quevedo JF, Vile RG, Wiseman GA, Stoian I, Pittelkow MR; Melanoma Study Group of the Mayo Clinic Cancer Center, Metastatic malignant melanoma. G Ital Dermatol Venereol, 144(1):1-26 2009
  • Benlhabib E, Hordinsky MK, Witthuhn BA, Anderson LB, Sekulic A, Squillace KA, Pittelkow MR, Wilcox GL. , Examination of ultraviolet B response in normal human keratinocytes utilizing iTRAQ combined to 2D LC-MS/MS J Invest Dermatol 128(Suppl 1):S203 2008
  • Sekulic A, Bittner M, Bruhn L, Pittelkow M, Trent J, Identification of growth-promoting networks differentially activated in CDKN2A wild-type melanoma tumors J Invest Dermatol 128(Suppl 1):S226. 2008
  • Carpenter S, Pockaj B, Dueck A, Gray R, Kurtz D, Sekulic A, Casey W. , Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome? Am J Surg 196(6):834-42;discussion 842-3 2008
  • Sekulic A, Haluska P Jr., Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, Swanson DL, Pockaj BA, Laman SD, Pittelkow MR, Markovic SN. Melanoma Study Group of Mayo Clinic Cancer Center., Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clinic Proceedings 83 (7):825-46 2008
  • Kennedy AP, Sekulic A, Irvin BJ, Nilson AE, Dilworth SM, Abraham RT. , Polyomavirus middle T antigen as a probe for T cell antigen receptor-coupled signaling pathways. J Biol Chem, 273x(19):11505-13 1998
  • Hosoi H, Dilling MB, Liu LN, Danks MK, Shikata T, Sekulic A, Abraham RT, Lawrence JC Jr, Houghton PJ., Studies on the mechanism of resistance to rapamycin in human cancer cells Mol Pharmacol 54(5): 815-24. 1998
  • Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC, Abraham RT. , Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277(5322):99-101 1997
Back To Top